Literature DB >> 110570

Effects of vasoactive intestinal polypeptide (VIP) on lower esophageal sphincter in awake baboons: comparison with glucagon and secretin.

S R Siegel, F C Brown, D O Castell, L F Johnson, S I Said.   

Abstract

The effects of vasoactive intestinal polypeptide (VIP), glucagon, and secretin on lower esophageal sphincter pressure were investigated in awake baboons. The three hormones were compared with respect to effect on (1) resting lower esophageal sphincter pressure and (2) maximal stimulatory response to pentagastrin. VIP was shown to reduce resting and pentagastrin-stimulated lower esophageal sphincter pressure with significantly greater potency than either secretin or glucagon. For reduction of resting lower esophageal sphincter pressure, the potency ratio of VIP to secretin was 16:1 and of VIP to glucagon was 32:1 (P less than 0.05). For inhibition of pentagastrin-stimulated sphincter pressure, the potency ratio of VIP to secretin was 32:1 and of VIP to glucagon was 64:1 (P less than 0.02). This demonstration of significantly increased potency of VIP over known inhibitory hormones strengthens the suggestion that VIP may have a physiologic role in the control of lower esophageal sphincter function.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 110570     DOI： 10.1007/bf01297119

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  12 in total

1.  Histaminergic pharmacology of primate lower esophageal sphincter.

Authors:  F C Brown; A Dubois; D O Castell
Journal:  Am J Physiol       Date:  1978-07

2.  Cellular localization of a vasoactive intestinal peptide in the mammalian and avian gastrointestinal tract.

Authors:  J M Polak; A G Pearse; J C Garaud; S R Bloom
Journal:  Gut       Date:  1974-09       Impact factor: 23.059

3.  Nature and kinetics of inhibition of lower esophageal sphincter pressure by glucagon.

Authors:  S S Jaffer; G M Makhlouf; B A Schorr; A M Zfass
Journal:  Gastroenterology       Date:  1974-07       Impact factor: 22.682

4.  Hyperglycemic and glycogenolytic effects of vasoactive intestinal polypeptide.

Authors:  C Kerins; S I Said
Journal:  Proc Soc Exp Biol Med       Date:  1973-03

5.  Effect of vasoactive intestinal polypeptide.

Authors:  S Rattan; S I Said; R K Goyal
Journal:  Proc Soc Exp Biol Med       Date:  1977-05

6.  Vasoactive intestinal polypeptide in brain synaptosomes.

Authors:  A Giachetti; R N Rosenberg; S I Said
Journal:  Lancet       Date:  1976-10-02       Impact factor: 79.321

7.  Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance.

Authors:  M G Bryant; M M Polak; I Modlin; S R Bloom; R H Albuquerque; A G Pearse
Journal:  Lancet       Date:  1976-05-08       Impact factor: 79.321

8.  Muscle function and structure of the esophagus of the baboon (Papio anubis).

Authors:  F C Brown; R M Gideon; F A Voelker; D O Castell
Journal:  Am J Vet Res       Date:  1978-07       Impact factor: 1.156

9.  Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons.

Authors:  L I Larsson; J Fahrenkrug; O Schaffalitzky De Muckadell; F Sundler; R Håkanson; J R Rehfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

10.  Peptidergic (VIP) innervation of the esophagus.

Authors:  R Uddman; J Alumets; L Edvinsson; R Håkanson; F Sundler
Journal:  Gastroenterology       Date:  1978-07       Impact factor: 22.682
View more
  2 in total

Review 1.  What's new in the esophagus.

Authors:  J Dent
Journal:  Dig Dis Sci       Date:  1981-02       Impact factor: 3.199

Review 2.  Primary oesophageal motility disorders. Current therapeutic concepts.

Authors:  M Traube; R W McCallum
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.